AR030024A1 - Una combinacion sinergetica: gabapentina y pregabalina - Google Patents

Una combinacion sinergetica: gabapentina y pregabalina

Info

Publication number: AR030024A1
Authority: AR; Argentina
Prior art keywords: treatment; pregabalin; gabapentin; ratio; pregabalina
Prior art date: 1999-07-02

Application number

ARP000103359A

Other languages

English (en)

Spanish (es)

Inventor

Roger N Brummel

Lakhbir Singh

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-02

Filing date

2000-06-30

Publication date

2003-08-13

2000-06-30 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2003-08-13 Publication of AR030024A1 publication Critical patent/AR030024A1/es

Links

UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title abstract 5
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title abstract 3
230000002195 synergetic effect Effects 0.000 title abstract 2
208000004454 Hyperalgesia Diseases 0.000 abstract 2
229960002870 gabapentin Drugs 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
229960001233 pregabalin Drugs 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
208000000094 Chronic Pain Diseases 0.000 abstract 1
208000035154 Hyperesthesia Diseases 0.000 abstract 1
206010065390 Inflammatory pain Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
208000005298 acute pain Diseases 0.000 abstract 1
206010053552 allodynia Diseases 0.000 abstract 1
239000002775 capsule Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000000839 emulsion Substances 0.000 abstract 1
239000008187 granular material Substances 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000036407 pain Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000006187 pill Substances 0.000 abstract 1
-1 sachets Substances 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1
239000000829 suppository Substances 0.000 abstract 1
239000000725 suspension Substances 0.000 abstract 1
239000003826 tablet Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ARP000103359A 1999-07-02 2000-06-30 Una combinacion sinergetica: gabapentina y pregabalina AR030024A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US14221599P	1999-07-02	1999-07-02

Publications (1)

Publication Number	Publication Date
AR030024A1 true AR030024A1 (es)	2003-08-13

Family

ID=22499016

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP000103359A AR030024A1 (es)	1999-07-02	2000-06-30	Una combinacion sinergetica: gabapentina y pregabalina

Country Status (14)

Country	Link
EP (1)	EP1196160B1 (de)
JP (1)	JP2003503453A (de)
AR (1)	AR030024A1 (de)
AT (1)	ATE313322T1 (de)
AU (1)	AU5753900A (de)
BR (1)	BR0012058A (de)
CA (1)	CA2373953A1 (de)
CO (1)	CO5210869A1 (de)
DE (1)	DE60024995T2 (de)
ES (1)	ES2255500T3 (de)
MX (1)	MXPA02000170A (de)
PE (1)	PE20010331A1 (de)
UY (1)	UY26230A1 (de)
WO (1)	WO2001001983A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL189872B1 (pl)	1996-07-24	2005-10-31	Warner Lambert Co	Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
JP4428053B2 (ja) *	2002-02-05	2010-03-10	味の素株式会社	ガバペンチン若しくはプレガバリンおよびｎ型カルシウムチャンネル拮抗剤を含有する医薬組成物
US7687080B2 (en) *	2002-11-25	2010-03-30	Taraxos Inc.	Treatment of neuropathy
AU2004224322A1 (en) *	2003-03-21	2004-10-07	Dynogen Pharmaceuticals, Inc.	Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
US20060264509A1 (en) *	2003-03-21	2006-11-23	Fraser Matthew O	Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
WO2004084881A1 (en) *	2003-03-21	2004-10-07	Dynogen Pharmaceuticals, Inc.	METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
JP2005060311A (ja) *	2003-08-13	2005-03-10	Mochida Pharmaceut Co Ltd	Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
DE102007019071A1 (de) *	2007-04-23	2008-10-30	Ratiopharm Gmbh	Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
WO2010036937A1 (en)	2008-09-27	2010-04-01	Taraxos Inc.	Topical formulations for treatment of neuropathy
WO2010115612A2 (en) *	2009-04-10	2010-10-14	Synthon B.V.	Pregabalin compositions
SG10201510665WA (en)	2009-12-04	2016-01-28	Sunovion Pharmaceuticals Inc	Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6194459B1 (en) *	1997-08-19	2001-02-27	Warner-Lambert Company	Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
DE19802327A1 (de) *	1998-01-23	1999-07-29	Goedecke Ag	Synergistische Arzneimittelzubereitung mit analgetischer Wirkung
US6451857B1 (en) *	1999-03-10	2002-09-17	Warner-Lambert Company	Analgesic compositions comprising anti-epileptic compounds and methods of using same

2000
- 2000-06-21 DE DE60024995T patent/DE60024995T2/de not_active Expired - Fee Related
- 2000-06-21 ES ES00943001T patent/ES2255500T3/es not_active Expired - Lifetime
- 2000-06-21 WO PCT/US2000/017039 patent/WO2001001983A1/en not_active Ceased
- 2000-06-21 AT AT00943001T patent/ATE313322T1/de not_active IP Right Cessation
- 2000-06-21 AU AU57539/00A patent/AU5753900A/en not_active Abandoned
- 2000-06-21 JP JP2001507475A patent/JP2003503453A/ja not_active Abandoned
- 2000-06-21 CA CA002373953A patent/CA2373953A1/en not_active Abandoned
- 2000-06-21 BR BR0012058-8A patent/BR0012058A/pt not_active Application Discontinuation
- 2000-06-21 EP EP00943001A patent/EP1196160B1/de not_active Expired - Lifetime
- 2000-06-21 MX MXPA02000170A patent/MXPA02000170A/es active IP Right Grant
- 2000-06-28 PE PE2000000651A patent/PE20010331A1/es not_active Application Discontinuation
- 2000-06-30 CO CO00049385A patent/CO5210869A1/es not_active Application Discontinuation
- 2000-06-30 UY UY26230A patent/UY26230A1/es not_active Application Discontinuation
- 2000-06-30 AR ARP000103359A patent/AR030024A1/es unknown

Also Published As

Publication number	Publication date
EP1196160B1 (de)	2005-12-21
ATE313322T1 (de)	2006-01-15
WO2001001983A1 (en)	2001-01-11
CA2373953A1 (en)	2001-01-11
DE60024995T2 (de)	2006-06-22
DE60024995D1 (de)	2006-01-26
AU5753900A (en)	2001-01-22
ES2255500T3 (es)	2006-07-01
UY26230A1 (es)	2001-03-16
JP2003503453A (ja)	2003-01-28
CO5210869A1 (es)	2002-10-30
EP1196160A1 (de)	2002-04-17
BR0012058A (pt)	2002-05-14
MXPA02000170A (es)	2002-07-02
PE20010331A1 (es)	2001-03-22

Similar Documents

Publication	Publication Date	Title
CO2023000199A2 (es)	2023-04-17	Péptidos funcionalizados como agentes antivirales
ES2719900T3 (es)	2019-07-16	Combinación farmacéutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y pregabalina o gabapentina
AR030024A1 (es)	2003-08-13	Una combinacion sinergetica: gabapentina y pregabalina
CO2023008018A2 (es)	2023-07-10	Nuevos agentes antivirales derivados de la espiropirrolidina
CO2023002852A2 (es)	2023-06-09	Péptidos funcionalizados como agentes antivirales
AR039164A1 (es)	2005-02-09	Sales de venlafaxina de baja solubilidad en agua
CO6241105A2 (es)	2011-01-20	"composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea y un anticoagulante u otro agente antiplaquetario"
HRP20110271T1 (hr)	2011-05-31	Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek)
AR031450A1 (es)	2003-09-24	Composiciones orales que tienen caracteristicas esteticas del consumidor mejoradas
RU2010138638A (ru)	2012-04-20	Новые применения 4-фенилбутирата натрия (4фб) и его фармацевтически приемлемых солей
WO2007056232B1 (en)	2007-11-08	Methods of using saha and bortezomib for treating cancer
AR028504A2 (es)	2003-05-14	Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
UY27374A1 (es)	2003-03-31	Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales
AR039633A2 (es)	2005-03-02	Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
AR127247A1 (es)	2024-01-03	Inhibidores de cdk2 de ciclopentilpirazol
AR095159A2 (es)	2015-09-30	Una composición farmacéutica en forma de cápsula para administración oral
UY39864A (es)	2023-02-28	Nuevos agentes antivirales derivados de espiropirrolidina
PE20020387A1 (es)	2002-06-24	Uso de una combinacion de salmeterol y fluticasona
AR041069A1 (es)	2005-04-27	Composicion de tolterodina liquida oral
ES2078019T3 (es)	1995-12-01	Amidas de alcanoil l-carnitina con aminoacidos y composiciones farmaceuticas que las contienen para promover regeneracion del tejido nervioso, inhibir degeneracion neuronal, mejorar el proceso de aprendimiento y memoria y para el tratamiento de coma.
CO6400019A1 (es)	2012-03-15	Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion
ES2268732T3 (es)	2007-03-16	Tratamiento de desordenes maniacos.
WO2020055226A1 (es)	2020-03-19	Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona
JP2003503453A5 (ja)	2007-07-26	ガバペンチンおよびプレガバリンを含む相乗作用組成物
AR132497A1 (es)	2025-07-02	Combinación de obicetrapib amorfo e inhibidor de sglt2

Legal Events

Date	Code	Title	Description
2012-07-19	FB	Suspension of granting procedure